Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201

Overview of attention for article published in Journal of Clinical Oncology, July 2025

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (94th percentile)
High Attention Score compared to outputs of the same age and source (85th percentile)

Mentioned by

news: 3 news outlets
twitter: 16 X users

bluesky: 3 Bluesky users

Readers on

mendeley: 74 Mendeley

So far, Altmetric has seen 3 news stories from 3 outlets.

Kombinacja avutometinibu i defactinibu w leczeniu pacjentek z nawrotowym LGSOC

Termedia, 26 Aug 2025

lek. Sylwia Kopeć Data: 26.08.2025 Źródło: Banerjee SN, Van Nieuwenhuysen E, Aghajanian C, Efficacy and Safety of Avutometinib ±…

Avutometinib/Defactinib Shows SOC Potential in LG Serous Ovarian Cancer

Oncology Nursing News, 11 Aug 2025

Nausea, diarrhea, peripheral edema, and rash were common among patients taking avutometinib and defactinib.

Avutometinib/Defactinib Display Safety, Efficacy in Ovarian Cancer Subtype

Cancer Network, 14 Jul 2025

Among patients treated with the combination therapy, the median progression-free survival was 12.9 months.

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity.